Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure.
Guedeney P, Farjat-Pasos JI, Asslo G, Roule V, Beygui F, Hermida A, Gabrion P, Leborgne L, Houde C, Huang F, Lattuca B, Leclercq F, Mesnier J, Abtan J, Rouanet S, Hammoudi N, Collet JP, Zeitouni M, Silvain J, Montalescot G, Rodés-Cabau J; AIR-FORCE Task Force. Guedeney P, et al. Among authors: hammoudi n. Eur Heart J Cardiovasc Pharmacother. 2023 Nov 2;9(7):601-607. doi: 10.1093/ehjcvp/pvad023. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36963773
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.
Helft G, Steg PG, Le Feuvre C, Georges JL, Carrie D, Dreyfus X, Furber A, Leclercq F, Eltchaninoff H, Falquier JF, Henry P, Cattan S, Sebagh L, Michel PL, Tuambilangana A, Hammoudi N, Boccara F, Cayla G, Douard H, Diallo A, Berman E, Komajda M, Metzger JP, Vicaut E; OPTImal DUAL Antiplatelet Therapy Trial Investigators. Helft G, et al. Among authors: hammoudi n. Eur Heart J. 2016 Jan 21;37(4):365-74. doi: 10.1093/eurheartj/ehv481. Epub 2015 Sep 12. Eur Heart J. 2016. PMID: 26364288 Clinical Trial.
Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P, Logeart D, Gandjbakhch E, Bernard C, Hatem SN, Isnard R, Cluzel P, Le Feuvre C, Leprince P, Hammoudi N, Lemoine FM, Klatzmann D, Vicaut E, Komajda M, Montalescot G, Lompré AM, Hajjar RJ; AGENT-HF Investigators. Hulot JS, et al. Among authors: hammoudi n. Eur J Heart Fail. 2017 Nov;19(11):1534-1541. doi: 10.1002/ejhf.826. Epub 2017 Apr 10. Eur J Heart Fail. 2017. PMID: 28393439 Free article. Clinical Trial.
Cardiac manifestations in sickle cell disease varies with patient genotype.
Guedeney P, Lionnet F, Ceccaldi A, Stankovic Stojanovic K, Cohen A, Mattioni S, Montalescot G, Bachmeyer C, Isnard R, Haymann JP, Hammoudi N. Guedeney P, et al. Among authors: hammoudi n. Br J Haematol. 2018 Jun;181(5):664-671. doi: 10.1111/bjh.15238. Epub 2018 Apr 20. Br J Haematol. 2018. PMID: 29676452 Free article. Clinical Trial.
The times they are a changin'.
Hammoudi N, Montalescot G. Hammoudi N, et al. Eur Heart J. 2018 May 14;39(19):1736-1739. doi: 10.1093/eurheartj/ehy216. Eur Heart J. 2018. PMID: 29762701 No abstract available.
Copeptin as a prognostic biomarker in acute myocardial infarction.
Lattuca B, Sy V, Nguyen LS, Bernard M, Zeitouni M, Overtchouk P, Yan Y, Hammoudi N, Ceccaldi A, Collet JP, Kerneis M, Diallo A, Montalescot G, Silvain J. Lattuca B, et al. Among authors: hammoudi n. Int J Cardiol. 2019 Jan 1;274:337-341. doi: 10.1016/j.ijcard.2018.09.022. Epub 2018 Sep 6. Int J Cardiol. 2019. PMID: 30217427
186 results